These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36046924)

  • 1. Safety of subcutaneous immunotherapy with carbamylated allergoids based on data from a pharmacovigilance database.
    Franco F; Cristoforo I; Francesca S; Arianna P; Laura M; Carlo C; Simonetta M; Enrico C
    Immunotherapy; 2022 Oct; 14(15):1219-1224. PubMed ID: 36046924
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of carbamylated monomeric allergoids for sublingual immunotherapy. Data from a pharmacovigilance study.
    Compalati E; Incorvaia C; Urbano S; Strada P; Frati F
    Immunotherapy; 2020 Feb; 12(3):195-202. PubMed ID: 31969034
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of allergoid immunotherapy: is cat allergy a suitable target?
    Nguyen NT; Raskopf E; Shah-Hosseini K; Zadoyan G; Mösges R
    Immunotherapy; 2016; 8(3):331-49. PubMed ID: 26860435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
    Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
    Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.
    Heldner A; Alessandrini F; Russkamp D; Heine S; Schnautz B; Chaker A; Mwange J; Carreno Velazquez TL; Heath MD; Skinner MA; Kramer MF; Zissler UM; Schmidt-Weber CB; Blank S
    Allergy; 2022 Mar; 77(3):907-919. PubMed ID: 34287971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of allergoids in allergen immunotherapy: from injective to sublingual route.
    Compalati E; Incorvaia C; Cavaliere C; Masieri S; Gargiulo A; Mistrello G; Frati F
    Eur Ann Allergy Clin Immunol; 2020 Sep; 52(5):195-204. PubMed ID: 32338477
    [No Abstract]   [Full Text] [Related]  

  • 7. Allergoids for Allergy Treatment.
    Carnes J; Gallego MT; Moya R; Iraola V
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):110-119. PubMed ID: 29473530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
    Mösges R; Ritter B; Kayoko G; Allekotte S
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality requirements for allergen extracts and allergoids for allergen immunotherapy.
    Zimmer J; Bonertz A; Vieths S
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():4-11. PubMed ID: 29128092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
    Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
    Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy.
    Henmar H; Lund G; Lund L; Petersen A; Würtzen PA
    Clin Exp Immunol; 2008 Sep; 153(3):316-23. PubMed ID: 18647321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific allergen immunotherapy for the treatment of atopic eczema.
    Tam H; Calderon MA; Manikam L; Nankervis H; García Núñez I; Williams HC; Durham S; Boyle RJ
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008774. PubMed ID: 26871981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of Russian allergoids for the specific immunotherapy of pollinosis].
    Fradkin VA; Roshal' NI; Goriachkina LA; Nikonorova MV; Astaf'eva NG; Luss LV; Raĭkis VN
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (5):101-5. PubMed ID: 8067129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific immunotherapy with depigmented allergoids].
    Klimek L; Thorn C; Pfaar O
    HNO; 2010 Jan; 58(1):51-6. PubMed ID: 20011999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.
    Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S
    Allergy; 2018 Sep; 73(9):1812-1822. PubMed ID: 29779247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.
    Lund L; Henmar H; Würtzen PA; Lund G; Hjortskov N; Larsen JN
    Clin Exp Allergy; 2007 Apr; 37(4):564-71. PubMed ID: 17430354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment.
    Rodríguez Del Río P; Vidal C; Just J; Tabar AI; Sanchez-Machin I; Eberle P; Borja J; Bubel P; Pfaar O; Demoly P; Calderón MA
    Pediatr Allergy Immunol; 2017 Feb; 28(1):60-70. PubMed ID: 27637414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells.
    Heydenreich B; Bellinghausen I; Lorenz S; Henmar H; Strand D; Würtzen PA; Saloga J
    Immunology; 2012 Jun; 136(2):208-17. PubMed ID: 22348538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.